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Abstract 
The alphaherpesvirus that causes chicken pox and shingles, varicella-zoster virus 
(VZV), infects skin fibroblasts and keratinocytes.  These cells are typically 
quiescent and it is known that VZV manipulates their intracellular environment 
to activate MAPK signaling cascades, cell cycle regulators, and many 
transcription factors for its replication.  We hypothesized that inhibition of cell 
kinases would prevent VZV replication and also elucidate which pathways are 
most important.  We evaluated 80 kinase inhibitors for cytotoxicity and anti-
proliferative effects on human foreskin fibroblasts, and then determined their 
antiviral efficacy against VZV-ORF9-Luc strain.  Ten well-tolerated, potent 
kinase inhibitors whose targets are critical mediators of VZV infection were 
identified.  Receptor tyrosine kinases (EGFRK, NGFRK and PDGFRK) were 
pivotal for VZV replication and 3 potent compounds inhibited these targets 
(Tyrphostin AG1478, AG-879, Tyrphostin 9).  Their common downstream 
substrates were also found to be necessary for VZV replication: protein kinase A 
(PKA, H-89•2HCl) and protein kinase C (PKC, GF 109203X and PKC-412).  
Other potent compounds blocked the activity of calmodulin-dependent protein 
kinase (CaMKII, KN-62) and glycogen synthase kinase 3-beta (GSK-3β, 
Indirubin-3’-monooxime and Kenpaullone).  We also identified one compound 
with previously known antiviral activity, the cyclin-dependent kinase inhibitor 
Roscovitine.  Thus VZV infection causes changes in the intracellular 
environment that expose antiviral targets in multiple pathways.  
 
This abstract was presented at the 27
th
 International Conference on Antiviral 
Research, May 12-16, 2014, Raleigh, NC. 
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4 
Executive Summary 
 
 Varicella-zoster virus (VZV) is a human-restricted herpesvirus that 
causes chickenpox (varicella) and shingles (zoster).  Primary viral infection 
results in chickenpox, a generally mild disease that is typically contracted during 
childhood and presents with scattered, itchy skin pustules.  Following initial 
infection, VZV, like other viruses in the herpes family, becomes dormant in 
nerve cells.  The virus can reactivate spontaneously to cause shingles, a disease 
characterized by a localized, painful skin rash.  The most common complication 
associated with shingles is postherpetic neuralgia (PHN)the persistence of 
debilitating pain for months or years even after the infection and rash have 
resolved. 
 The Centers for Disease Control and Prevention (CDC) estimate that 3.5 
million cases of varicella occur every year and that by age 40, the virus has 
infected 99.5% of people born in the U.S.  Approximately one in three people 
will develop shingles in their lifetime, leading to one million cases each year in 
this country.  The incidence of zoster and PHN increases with age, and with 
millions of ‘baby boomers’ set to join the group at the highest risk, the 
development of more effective antiviral drugs is crucial.  
 Problems associated with the vaccines and current antiviral medications 
necessitate new methods of treatment.  The varicella vaccines, Varivax and 
Zostavax, consist of a live virus that cannot be given to people who are 
immunocompromised, although they have a very high risk for zoster.  The 
shingles vaccine is only approved for individuals over 50 years old, and zoster 
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occurs even in about half of people who are immunized.  Acyclovir, the primary 
medication used to treat zoster, is effective only within 48 hours after the onset of 
symptoms, and this drug is ten times less potent against VZV than other 
herpesviruses.   Although the vaccines have prevented many cases of chicken 
pox and shingles, and acyclovir has helped some people recover from the 
infections, there is a compelling need for new treatments for this virus. 
 VZV, like all viruses, cannot replicate outside of a living host—it lacks 
the machinery necessary to carry out its own reproductive processes and must 
hijack the infrastructure of host cells.  In so doing, it activates host kinases that 
send signals throughout the cell to facilitate viral replication mechanisms.  
Kinases are proteins that transfer high-energy phosphate groups to specific 
substrates, a reaction that typically ‘turns on’ its target.  These kinases are 
typically linked into cascades that transduce signals from a cell’s exterior to 
intracellular effectors, which in the case of VZV infection are factors necessary 
for replication of viral DNA and the production of viral proteins.  VZV is known 
to activate specific kinases during its life cycle to gain access to these mediators, 
but there are inevitably more that have yet to be identified.   
The goal of this project, therefore, was to elucidate additional kinases 
important in VZV replication by inhibiting their activity with compounds that 
block their ability to transfer phosphate groups.  This way, we could assess the 
relative importance of specific targets in the viral life cycle.  We hoped that by 
identifying the most essential kinases we could expand our knowledge of VZV-
host interactions and identify potential targets of antiviral drugs. 
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 To do this, we purchased eighty kinase-inhibiting compounds with well-
defined targets.  The first step in the process was to assess the safety of each 
compound in lab-grown human fibroblasts, a type of skin cell.  This was crucial 
because compounds that killed cells they were meant to treat would likely cause 
significant side effects in patients.  We compared drug-treated cells with non-
treated cells to determine the effect of each inhibitor on cell viability.  We then 
eliminated compounds that were toxic since they would be of little value in a 
medical setting.   
 Next, we studied the effect of non-toxic compounds on cell division.  
Cellular division, of course, is an essential process of living organisms in which 
kinases play a particularly important role.  To make sure that inhibiting specific 
proteins did not prevent normal cellular proliferation, we measured the amount of 
cell division that took place in drug-treated fibroblasts after 48 hours.  Drugs that 
prevented an increase in the number of cells relative to the beginning of the 
experiment were removed from the study because they, too, would likely be 
disadvantageous in a clinical setting.   
 Seventy of the original eighty inhibitors were nontoxic in these tests.  We 
subsequently determined the antiviral efficacy of the remaining compounds in 
VZV-infected skin cells.  We found a wide range of antiviral activity exhibited 
by the inhibitors and narrowed our focus to the sixteen most potent compounds.  
For each of the most effective compounds, we calculated a Selectivity Index (SI), 
which measures a compound’s ability to prevent viral processes without 
deleteriously affecting the host.  This step identified ten compounds whose 
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targets represent important mediators in VZV replication.  Excitingly, a number 
of these proteins were implicated by more than one compound, which confirms 
the importance of their role in virus replication. 
The cellular targets implicated by our findings are constituents of 
multiple signaling pathways, a number of which were previously unidentified as 
mediators of VZV replication.  Moreover, the kinases we identified as important 
antiviral targets act at multiple levels of these pathways and are capable of 
eliciting a variety of responses that are crucial in the viral life cycle.  Given the 
hierarchical nature of these cascade proteins, it is possible that combining 
inhibitors to block multiple kinases at the same time would result in synergistic 
antiviral effects.  Drug therapy targeting host cell functions is particularly 
promising because viruses are much less likely to develop resistance to these 
drugs than current antiviral medications.  It is our hope that the identification of 
these antiviral targets will ultimately lead to novel clinical treatments of 
chickenpox and shingles. 
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Introduction 
Varicella-zoster virus (VZV) is an alphaherpesvirus that causes both 
chicken pox (varicella) and shingles (herpes zoster).  The virus is highly 
contagious and is spread primarily through aerosols and contact with infected 
skin lesions.  Varicella is a common illness that is typically acquired during 
childhood.  The Centers for Disease Control and Prevention (CDC) estimate that 
approximately 3.5 million new cases of chicken pox develop each year.  
Varicella has an incubation period of 10-21 days and presents with systemic, 
itchy skin lesions and fever and, although the disease is generally mild, can cause 
severe complications or even death, particularly in people who are older or 
immunocompromised (Balfour, 1988; De La Blanchardiere et al., 2000).  
Varicella also poses a threat to pregnant women, developing fetuses, and 
newborns, since perinatal transmission may cause severe neurological defects 
and organ damage (Gnann, 2002).   
The virus establishes latency in dorsal root ganglia following initial 
varicella infection and can reactivate spontaneously years or decades later as 
zoster.  Anyone with prior exposure to live virus is at risk for developing 
shingles.  This is of particular concern because the CDC estimates that 99.5% of 
American-born citizens over the age of 40 have had varicella.  The mechanisms 
and causes of reactivation are incompletely understood but once VZV is 
acquired, the threat of a reemerging infection remains for life.  Reactivation of 
dormant virus can be the result of physical or psychological stress, the loss of 
cell-mediated immunity caused by immunosuppression or senescence, as well as 
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a number of other genetic and demographic factors (Thomas & Hall, 2004).  
Zoster is characterized by a painful, vesicular rash in localized regions of the 
body, typically along a dermatome enervated by the ganglion where latency was 
established.  Complications of zoster include facial paralysis, pneumonia, 
encephalitis, and vision loss (Gnann, 2002; Volpi, 2007), although such serious 
problems are rare.  The most common complication associated with zoster, 
however, is postherpetic neuralgia (PHN), a debilitating condition characterized 
by pain in the affected region that can persist for months or years even after the 
resolution of infection and skin lesions (Tenser, 2001).  The incidence of herpes 
zoster in the United States is rising, with total cases increasing across all age 
groups between 1993 and 2006 (Leung et al., 2011; Yih et al., 2005).  The CDC 
approximates the incidence of zoster in the US at 4 cases per 1000 persons 
annually and 10 cases per 1000 persons over the age of 60, with an estimated 1 
million total cases occurring each year (2014).  The CDC now estimates that 1 in 
3 people will develop shingles in their lifetime.   
Vaccines against varicella and zoster have proven effective in reducing 
annual cases of VZV infection and associated complications but come with their 
own problems.  The varicella vaccine, Varivax (Merck), has substantially 
reduced the incidence of varicella-associated mortality and morbidity in the US 
since its use began in 1995 (Davis et al., 2004; Nguyen et al., 2005).  However, 
breakthrough cases occur in 15-20% of inoculated individuals (Schmid & 
Jumaan, 2010; Ampofo et al., 2002).  Furthermore, because Varivax is a live 
virus, it is not 100% effective at preventing establishment of latent virus and 
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protecting against reactivation to zoster (Hambleton et al., 2008.) and live 
vaccines are not safe for immunocompromised patients.  The varicella vaccine 
may also be contributing to the recently observed rise in cases of herpes zoster by 
lowering the extent of exogenous VZV exposure, which may act as a natural 
“booster shot” for previously infected individuals (Wagenpfeil et al., 2004).  
Without this boost, cell-mediated immunity diminishes continuously with age 
and the risk of reactivation increases across the lifespan.  Data implicating the 
role of the varicella vaccine in this theory, however, have thus far proven 
inconclusive (Reynolds et al., 2008).  
 The zoster vaccine, Zostavax (Merck), is approximately 50% effective at 
preventing shingles and 90% effective against postherpetic neuralgia (Sanford & 
Keating, 2010), but the vaccine is only approved for people 50 and older.  While 
that covers most individuals at the highest risk, a large portion of susceptible 
hosts are not eligible to receive the vaccine.  In addition, Zostavax is expensive 
compared to other vaccines and is not covered by all insurance plans, further 
limiting access to it (Harvard Family Health Guide).  The zoster vaccine, like the 
varicella vaccine, also uses a live, attenuated virus and is not appropriate for 
inoculation of immunocompromised individuals who are at highest risk for 
reactivation. 
A number of antiviral medications are currently used for clinical 
treatment of varicella and zoster but like the vaccines, each presents their own 
challenges.  The most commonly used drugs, acyclovir, famciclovir, and 
valaciclovir, are modified to their active forms by the viral enzyme thymidine 
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kinase.  The active forms of these compounds are nucleoside analogues that 
incorporate into viral DNA and prevent replication.  Acyclovir, while useful in 
treating VZV infection, is ten times less effective against VZV than the related 
herpes simplex viruses, and, because it is poorly absorbed, must be administered 
five times a day (Arvin, 1996).  Famciclovir and valaciclovir are better absorbed 
than acyclovir but are not approved for use in treating zoster in 
immunocompromised patients (Arvin, 1996).  Furthermore, treatment with these 
drugs must be started within 96 hours after appearance of skin lesions to decrease 
the severity of illness.  These antivirals also do not prevent or remove latent virus 
and therefore offer no protection against viral reactivation (Arvin, 1996).   
These drugs have the advantage of selectively targeting VZV-infected 
cells but also promote the emergence of drug resistance.  The thymidine kinase 
gene is not essential for viral replication, so prolonged use of these nucleoside 
analogues can select for thymidine kinase-negative mutants that are unresponsive 
to acyclovir (Arvin, 1996).  Such acyclovir-resistant strains have indeed been 
well documented in immunocompromised patients (Linnemann et al., 1990; 
Léger et al., 2001; Pahwa et al., 1988).  Acyclovir-resistant infections can be 
treated with Foscarnet, a drug that is highly toxic and can cause significant 
metabolic side effects (Coen & Schaffer, 2003), making it a less than desirable 
alternative.   
The existence of these vaccines and antiviral medications, while 
important in minimizing the impact of varicella and zoster, has reduced the 
urgency for the development of safer and more effective drugs.  The problems 
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associated with the virus-centered method of current treatment programs 
necessitate a new approach.  To this end, a new paradigm has emerged in 
antiviral research-- the therapeutic targeting of host enzymes that are important 
mediators of viral replication.  Viruses are, by nature, obligate intracellular 
parasites and depend on the action of many host signal transduction pathways to 
carry out processes like gene expression, replication, and packaging (Münter et 
al., 2006).  Blocking access to host proteins involved in cellular signaling 
pathways has the potential to disrupt normal virus-host interactions that are 
essential for the viral life cycle.  This approach also has the advantage of 
presenting a more substantial barrier to the development of drug resistance than 
current treatments.  Viruses rely on host signaling machinery because they lack 
genes for the proteins that carry out replication processes.  It is unlikely that 
mutations in the VZV genome would give rise to resistance to these treatments 
because the virus is totally dependent on the activity of those specific proteins 
and has no way of subverting the signaling pathways when they are blocked.   
Given the importance of these virus-host interactions, the primary goal of 
this project was to identify cellular signaling pathways involved in VZV 
infection. Previous studies have shown that VZV affects the activity of host 
protein kinases involved in phosphorylation cascades (Zapata et al., 2007; Liu et 
al., 2012; Liu & Cohen, 2013) that regulate transcription, cell survival, and cell 
cycle progression among other processes.  With this information in mind, we 
hypothesized that we could elucidate specific pathways and mediators VZV uses 
for replication by evaluating a kinase inhibitor panel in cultured human skin 
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cells.  Similar approaches have been used in other areas of infectious disease 
research and are now accepted methods for studying pathogen-host pathway 
interactions (Hussain et al., 2010; Goswami et al., 2012).   
The goal of this project was to identify compounds that would be well 
tolerated by host cells but also effective at preventing viral replication.  Such 
compounds would point to a cellular target whose activity was more important to 
VZV than the host.  This difference in selectivity could be exploited in the 
clinical treatment of varicella and zoster.   
To perform the study, we purchased a kinase inhibitor library containing 
80 different compounds with well-defined molecular targets.  The first objective 
was to demonstrate which compounds could be safely administered to the skin 
cells without causing cell death or inhibiting growth.  The second objective was 
to test whether treatment with the kinase inhibitors resulted in a reduction of 
VZV infection.  The final objective was to further assess the in vitro therapeutic 
efficacy of the most potent drugs identified in the second step by quantifying 
their selectivity for interrupting viral replication over host processes.  Classifying 
the inhibitors in this way would allow us to discern the most important protein 
targets on which to focus future drug development efforts. 
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Materials and Methods 
Cell and Virus Culture.  Human foreskin fibroblasts (HFFs) (CCD-1137Sk; 
American Type Culture Collection, Manassas, VA) and MeWo cells, an 
immortalized human melanoma line, (a gift of Dr. Charles Grose, University of 
Iowa) were grown in Eagle minimum essential medium with Earle’s balanced 
salts and L-glutamine (HyClone Laboratories, Logan, UT) supplemented with 
10% heat-inactivated fetal bovine serum (FBS) (Benchmark FBS; Gemini Bio 
Products, West Sacramento, CA), amphotericin-B (250µg/mL), penicillin-
streptomycin (5000 IU/mL), and non-essential amino acid solution (all 
Mediatech, Manassas, VA) at 37
o
C under 5% CO2.  HFFs, a primary cell line, 
were grown for up to 20 passages.  VZV-BAC-Luc (Zhang et al., 2007) was 
derived from the Parental Oka strain, a wild type clinical isolate from Japan 
(Accession number: AB097933). Dr. Hua Zhu (University of Medicine and 
Dentistry of New Jersey) provided a master stock of VZV-BAC-Luc (passage 
10). VZV-BAC-Luc was stored at -80°C and grown on HFFs for up to 10 
passages. 
 
Drug Handling and Preparation.  A panel of 80 kinase inhibitors, the Screen-
Well® Kinase Inhibitor Library (Product Number: BML-2832-0100), was 
purchased from Enzo Life Sciences, Inc. (Farmingdale, NY).  Drugs were 
supplied as 100 µL of 10 mM stock dissolved in DMSO in deep, 96-well plates.  
We prepared 30 µL of 2 mM (MTT and Dose Response) and 10 mM (Neutral 
Red) replica plate aliquots for indicated assays.  The library and aliquots were 
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stored at -80
o
C and protected from light until use. Drugs in all experiments were 
thawed at room temperature before dilution to final concentration in complete 
tissue culture medium (TCM) at 37
o
C. 
 
Neutral Red (NR) Cytotoxicity Assay.  The NR assay was performed in clear, 
96-well plates with 5x10
3
 HFF cells/well.  The cells were cultured for 24 h until 
reaching confluence, and then the medium was removed and replaced with 200 
µL of medium containing the test drug.  Drugs were evaluated at 12.5, 25, 50, 
and 100 µM.  Four drugs were tested on each plate with inhibitors tested in 
triplicate and controls in replicates of six.  The outside wells were filled with 200 
µL of TCM during cell growth periods but received no cells or treatment (Figure 
1).  Following addition of drug, each plate was covered with an adhesive plastic 
sheet and incubated for 48 h.  The drugs were removed before the NR stain 
solution was added [93% TCM, 1% non-essential amino acids, 5% FBS, 1%  
Neutral Red (Sigma-Aldrich, St. Louis, MO) dissolved in Dulbecco’s Phosphate 
Buffered Saline with Ca
2+ 
and Mg
2+ 
(Mediatech Inc., Manassas, VA), filtered to 
clarify].  Neutral Red is absorbed by pinocytosis and accumulates in lysosomes; 
the amount of dye absorbed by the culture is proportional to the number of living 
cells.  250 µL of NR stain solution was added to each well and incubated for 2 h.  
Neutral Red solution was removed and cells were fixed with 250 µL of 0.5% 
formaldehyde (Fisher Scientific, Fair Lawn, NJ) in DPBS for 10 min at room 
temperature.  The fixative solution was removed and replaced with 100 µL of 
desorb solution [50% ethanol (Ultra Pure LLC, Darien, CT), 1% glacial acetic 
 
 
 
acid (Fisher Scientific, Fair Lawn, NJ) in distilled water].  Plates were then 
wrapped in aluminum foil and gently agitated on an orbital shaker for 25 min at 
room temperature.  
in each well was meas
All absorbance measurements were compared to a diluent (DMSO) negative 
control that showed no toxic effects and to a posit
which kills cells by apoptosis.
diluent were considered indicative of 
Figure 1. Plate layout of Neutral Red Assay
Diluent wells indicate DMSO
 
MTT Cellular Proliferation Assay.  
2,5-diphenyltetrazolium bromide
to assess the effect of all 80 inhibitors o
was performed in clear, 96
(1.67x10
3
cells/well)
 
Following desorption of the stain, the amount of NR present 
ured by a spectrophotometer with absorbance at 540 nm.  
ive control, staurosporine, 
  Absorbance values substantially lower than th
cytotoxicity. 
.  Stauro wells indicate staurosporine-treated
-treated negative controls.   
The MTT (3-(4,5-dimethylthiazol
) Cellular Proliferation Assay is 
n cell growth and division.  The assay 
-well plates on sub-confluent HFFs 
 that were cultured for 24 h.  A Time 0 replicate plate for 
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 positive controls.  
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each experiment was prepared for an initial measurement of cell number before 
drug was added.  Each data point of the Time 0 plate was the average of 6 
replicate wells.  Following initial incubation, seeding media was removed and 
replaced with 200 µL of drug solution.  Drugs were tested at 1.5, 3, 6, and 12 µM 
in triplicate wells.  The outside wells were filled with 200 µL of TCM during cell 
growth periods but received no cells or treatment (Fig. 2).  Following addition of 
drug, each plate was covered with an adhesive plastic sheet and incubated for 48 
h.  Twenty µL of 5 mg/mL MTT dissolved in PBS was added on top of existing 
drug solution and incubated for 3.5 h.  MTT is a yellow tetrazolium salt that is 
absorbed and reduced to a purple formazan in metabolically active, dividing cells 
by dehydrogenase and reductase enzymes.  Solutions were then removed and 
replaced with 150 µL of DMSO, a solvent of MTT.  Plates were wrapped in 
aluminum foil and gently agitated on an orbital shaker for 15 min at room 
temperature.  Once solubilized by the addition of DMSO, the amount of 
formazan was measured by a spectrophotometer. Absorbance was measured at 
590 nm.  The same quantification procedure was followed for 0 and 48 hour 
plates.  Non-dividing cells do not reduce the solution and thus produce less 
formazan.  Therefore, the absorbance is proportional to the amount of 
proliferative cells present.  Absorbance measurements of treated wells were then 
compared to controls of 1 mM phosphonoformate (PFA), a compound that does 
not inhibit cell division, and blank wells receiving only TCM and MTT solution 
and ultimately assessed against absorbance measured in the Time 0 samples. 
 
 
 
Figure 2. Plate layout of MTT Assay.
with MTT as a negative control
 
Dose-Response Assay. 
well plates with 2.5x10
screening process to assess antiviral efficacy of non
drugs. The strain of virus used in this assay encodes the gene for firefly 
luciferase, an enzyme that cleaves the D
releases photons that can be measured with bioluminescence imaging.  Upon the 
addition of D-luciferin, cells that express the luciferase enzyme emit photons in 
proportion to the amount of VZV infection.  Photon emission measu
were used to calculate VZV yield.  
overnight for 24 h.  TCM was then removed and cells
of TCM containing sonicated, 
cytopathic effect (CPE) 
adsorbed for two hours at 37
viral media for final concentrations of 1.5, 3, 6, and 12 
 
  Wells marked as Blank contained no cells and were treated only 
.  PFA wells received phosphonoformate as a positive control. 
 The Dose-Response Assay was performed in black,
3
 HFF cells/well infected with VZV-ORF9
-toxic and non
-luciferin substrate-- a reaction that 
Cells were plated with TCM and grown 
 were infected with 
cell-free VZV-ORF9-Luc showing more than 80% 
at a 1:25 ratio of infected to uninfected cells and 
°C.  100 µL of drug solutions were added on top of 
µM in triplicate.  Controls 
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 96-
-Luc as a rapid 
-inhibitory 
rements 
100 µL 
 
 
 
of DMSO (diluent
PFA were used in replicates of six
diluent control in order to calculate percent VZV yield, with the average of 
diluent-treated values taken as 100%.  
of TCM during cell growth periods but received no cells or treatment (Fig. 3).  
Following addition of drug, each plate was covered with an adhesive plastic sheet 
and incubated for 48 h.  
imaging using the IVIS
Hopkinton, MA) and expressed as total flux (photons/sec
Figure 3. Plate layout of Dose Response Assay
with PFA received phospho
negative controls. 
 
EC50 Assay.  The EC
half.  To determine the EC
which the compounds were surveyed in the Dose Response Assay, as many of 
them reduced VZV yield more than 50% at 1.5 µM.  Drug concentrations used in 
 
) at the same concentration as the highest drug dose
.  Drug treatments were compared to the 
The outside wells were fill
VZV yield was then determined by bioluminescence 
-50
®
 instrument (Caliper Life Sciences/Xenogen, 
/steradian/cm
. All wells received media containing cell
noformate as a positive control.  Wells with Diluent indicate DMSO
50 is the concentration of a drug that reduces viral yield by 
50, it was necessary to lower the concentrations at 
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 and 1 mM 
ed with 200 µL 
2
).  
 
-free VZV.  Wells 
-treated 
 
 
 
this assay were two
of this concentration expansion was to find a range of 0
would allow the interpolation the EC
VZV yield from drug
wells, with the average measurement from the untreated wells taken as 100% 
viral yield.  The procedure of the assay was identical to that of the Dose 
Response assay with the exception that VZV
of infected to uninfected cell
versus the drug concentration on a Log
regression to estimate the EC
dilutions as the test plates accompanied each e
no effect on virus yield).
Figure 4. Plate layout of EC
also used for the DMSO control plates.
 
Statistical Analysis.  
2011 and GraphPad Prism 5.02 for Windows and 5.0b for Macintosh 
 
-fold dilutions ranging from 0.094-24 µM (Fig. 4). 
-100% viral yield that 
50 from a resulting dose response curve.  
-treated wells was compared to the yield from untreated 
-ORF9-Luc was used at a 1:20 
s.  Results were plotted as the percent virus yield 
10 scale, and then analyzed by non
50 value. A plate containing DMSO with the same 
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Software, San Diego, CA, www.graphpad.com).  Data points represent mean 
values and all error bars represent the standard deviation.  EC50 concentrations 
were determined by interpolation of non-linear regression curves and the 
Selectivity Index (SI) was calculated by dividing the cytotoxic concentration by 
the EC50 concentration. For drugs that were nontoxic at all levels of the NR 
Assay, 100 µM was applied as the cytotoxic concentration in calculating SI. 
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Results 
As an obligate intracellular parasite, VZV relies on intimate interactions with its 
host cell.  Limiting the viral life cycle by disrupting these relationships presents a 
unique set of challenges.  Unlike the previously mentioned antiviral drugs that 
target VZV-specific processes, the compounds in this study target host proteins.  
Inhibition of host kinases has the potential to shut down crucial pathways and 
cause a number of deleterious alterations of the intracellular environment, even 
in uninfected cells.  The primary objective in identifying cellular targets of VZV, 
therefore, was to determine which compounds could be safely administered 
within a range of concentrations that were both non-toxic and non-inhibitory to 
quiescent, uninfected cells.  For this reason, the NR Cytotoxicity and MTT 
Cellular Proliferation assays were performed in human foreskin fibroblasts 
(HFFs), which are primary cultured cells that serve as a good host for VZV 
infection.  The antiviral efficacy of nontoxic inhibitors was then assessed by the 
Dose Response Assay using VZV-ORF9-Luc infected HFFs.  The most potent 
drugs were selected for further analysis by the EC50 Assay to determine their 
efficacy as inhibitors of viral replication and to calculate a Selectivity Index, an 
industry-standard quantification of the concentration range between which a 
compound is antiviral and adequately tolerated by the cell. 
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Neutral Red Cytotoxicty Assay.  The NR Assay was performed in confluent 
HFFs to assess cytotoxicity of all 80 compounds.  For values that were not 
judged to be cytotoxic but were less than the diluent, we suspect that some of the 
reduction in cell number was due to anti-proliferative effects of the drugs at high 
doses that prevented HFFs from growing and completely filling the wells.  
Furthermore, because the ultimate goal was to test as many compounds as 
possible for antiviral effects, we allowed some absorbance values considerably 
lower than the diluent value to pass the NR Assay.  To qualify for further study, 
compounds had to be suitably nontoxic at 12.5 µM or higher.  Compounds failing 
either this test or the MTT Assay were not used in the antiviral assays.  
Compounds that serve to illustrate the application of selection criteria of the NR 
Assay are shown (Fig. 5).  Staurosporine was cytotoxic at all concentrations and 
thus was disqualified from antiviral assays.  Wortmannin was toxic from 25-100 
µM but was determined to be safe enough at 12.5 µM to warrant further study.  
Both AG-490 and Tyrphostin 9 passed at all concentrations.  Most compounds in 
the library showed minimal cytotoxic effects and qualified for additional analysis 
(Table 1). 
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Figure 5.  NR Assay for cytotoxicity.  Absorbance of cells treated with indicated compounds at four 
concentrations (100, 50, 25, and 12.5 µM).  Values are the average ± standard deviation of triplicate 
samples.  Diluent represents numerical average of all control samples.  Experimental measurements were 
compared to the diluent to determine degree of cell viability. 
 
MTT Cellular Proliferation Assay.  The MTT Assay was performed in sub-
confluent HFFs in order to assess the level at which each drug inhibited cellular 
division.  Cells were used at one-third the density of the NR Assay to give the 
cells space to divide.  All 48-hour measurements were compared to an 
accompanying Time 0 plate to assess the degree of proliferation.  Absorbance 
values below or equivalent to the Time 0 readings were interpreted as anti-
proliferative.  Compounds found to be anti-proliferative at 1.5 µM were 
disqualified.  Examples illustrating the process used in assessing drugs by the 
MTT Assay are shown (Fig 6).  Wortmannin was cytostatic at all concentrations 
tested.  Although it passed the NR Assay at 12.5 µM, these results disqualified 
Wortmannin from antiviral assays.  AG-490 and Tyrphostin 9 passed at all 
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concentrations.  Most drugs that passed the NR Assay were also found to be non-
inhibitory (Table 1). 
 
Figure 6.  MTT Assay for cell proliferation.  Absorbance of cells treated with indicated compounds at 
four concentrations (12, 3, 6, and 1.5 µM).  Values are the average ± standard deviation of triplicate 
samples.  Time 0 represents numerical average of all Time 0 absorbance values.  Experimental 
measurements were compared to Time 0 to determine extent of cell proliferation. 
 
Dose Response Assay.  Ten inhibitors that were determined to be cytotoxic or 
cytostatic at low levels by the NR and MTT Assays, respectively, were removed 
from the panel and the remaining 70 drugs were evaluated for their antiviral 
potential.  Drugs that reduced VZV yield to less than 20% at 12 µM were 
considered highly potent and were further analyzed by the EC50 Assay.  Drugs 
that did not meet this cutoff were disqualified.  Illustrative examples of antiviral 
analysis are shown (Fig 7).  AG-490 reduced viral yield to only ~50% at 12 µM, 
well above the required 20% needed for further study.  Tyrphostin 9 was a highly 
effective antiviral compound, nearly eliminating VZV infection at 12 µM.  
Indeed, the lowest concentration of Tryphostin 9 tested, 1.5 µM, reduced VZV 
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yield below 50%, indicating that the range of concentrations in this assay was too 
high for this potent compound.  Most of the drugs displayed an antiviral effect, 
with seventeen compounds demonstrating considerable potency (Table 1). 
 
Figure 7.  Percent VZV yield in cells treated with indicated compounds at four concentrations (1.5, 3, 6, and 
12 µM).  Photons/second of each compound at each concentration was divided by the average 
photons/second of diluent replicates on the plate on which it was tested to determine percent VZV yield 
 
 
 
EC50 Assay.  The EC50 Assay was performed on the 17 qualifying compounds to 
determine the concentration at which the inhibitors reduced viral yield by 50% 
for use in SI calculations.  The results for Tyrphostin 25 were inconclusive and 
could not be fitted to a sigmoidal curve, so its EC50 and SI were not calculated.  
For both Tyrphostin AG1478 and PKC-412, the EC50 appeared to be outside the 
bottom range of the assay, but an approximate EC50 was still interpolated from 
the regression fit of each drug.  An example of a dose response regression curve 
used to interpolate the EC50 is shown (Fig. 8).  An EC50 was reliably interpolated 
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Table 1.  Results of NR, MTT, and Dose Response Assays.  All cytotoxicity and growth arrest numbers 
represent the lowest concentration, in µM, in which the respective effect was observed.  Percent VZV yield 
represents data collected at 12 µM.  * SP 600125 was not removed because it was previously shown to have 
antiviral effects in VZV (Zapata et al., 2007). 
Compound Name Cytotoxicity Growth 
Arrest 
% VZV 
Yield 
Tyrphostin 9 >100 >12 0.9 
RG-1462 25 >12 2.0 
H-89  2HCl 50 12 2.6 
GF 109203X 50 >12 2.8 
Roscovitine 50 >12 5.3 
PKC-412 100 6 5.3 
Tyrphostin AG1478 100 12 6.0 
Tyrphostin 25 25 >12 7.0 
Terreic Acid 25 12 7.6 
Indirubin-3’-monooxime 50 12 8.5 
KN-93 25 >12 8.9 
Kenpaullone 100 3 11.6 
N9-isopropyl-olomoucine 50 >12 12.7 
KN-62 25 >12 12.8 
AG-879 100 >12 14.0 
Triciribine >100 12 16.9 
Tyrphostin 23 >100 >12 18.0 
U-0126 >100 >12 21.0 
AG-494 >100 12 21.0 
Lavendustin A 100 >12 21.0 
BML-259 50 12 21.0 
SP 600125
* 12.5 6 21.7 
Tyrphostin 47 >100 >12 23.0 
PP1 100 >12 23.1 
H-7  2HCl 50 >12 24.0 
ML-9  HCl 50 3 25.3 
HA-1077  2HCl >100 12 26.0 
ML-7  HCl 50 >12 26.4 
GW 5074 >100 >12 27.1 
SB-202190 100 12 29.2 
Tyrphostin 51 100 >12 31.0 
LY 294002 >100 12 31.0 
Tyrphostin AG1288 >100 6 31.0 
5,6-dichloro-1-β-D-ribofuranosylbenzimidazole 100 6 31.0 
SB-203580 100 >12 32.0 
Olomoucine >100 >12 32.0 
H-9  HCl 50 >12 33.0 
ZM 336372 100 6 34.6 
SU 4312 100 12 37.9 
Tyrphostin 1 >100 >12 39.0 
   
 
 
 
29
Compound Name Cytotoxicity Growth 
Arrest 
% VZV 
Yield 
HA-1004  2HCl >100 12 41.3 
PD-98059 >100 >12 42.0 
Y-27632  2HCl 50 12 42.6 
LFM-A13 >100 12 42.7 
Piceatannol 50 6 42.9 
2,2',3,3',4,4'-Hexahydroxy-1,1'-biphenyl-6,6'-
dimethanol dimethyl ether 
25 3 43.0 
Indirubin >100 3 43.3 
ZM 449829 100 >12 43.5 
2-Aminopurine >100 >12 44.0 
AG-126 >100 >12 48.0 
AG-1296 50 >12 49.0 
Apigenin 100 12 50.0 
SC-514 >100 12 50.4 
Daidzein >100 3 51.0 
2-Hydroxy-5-(2,5-dihydroxybenzylamino) 
benzoic acid 
100 12 51.0 
SU 1498 25 >12 51.9 
AG-490 >100 >12 52.0 
Genistein >100 3 53.0 
H-8 100 >12 53.7 
Tyrphostin 46 >100 >12 54.0 
Palmitoyl-DL-carnitine 100 >12 54.5 
Rapamycin 25 12 54.5 
Quercetin  2H2O >100 12 59.3 
Iso-olomoucine >100 12 59.8 
Tyrphostin AG1295 >100 12 62.0 
BML-257 >100 12 64.0 
AG-825 100 >12 65.0 
Hypericin 50 12 65.0 
Hydroxy-2-naphthalenylmethylphosphonic acid >100 6 72.9 
AG-370 >100 >12 112.0 
Wortmannin 25 <1.5 -- 
D-erythro-Sphingosine 12.5 6 -- 
PP2 12.5 6 -- 
Rottlerin 12.5 6 -- 
BAY 11-7082 12.5 6 -- 
BML-265 12.5 6 -- 
5-Iodotubericidin 12.5 3 -- 
Erbstatin analog 12.5 3 -- 
Staurosporine 12.5 <1.5 -- 
Ro 31-8220 mesylate 12.5 1.5 -- 
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from most regression curves (Table 2). 
  
Figure 8.  Non-linear regression of Tyrphostin 9 (R2 = .9144).  Concentrations are in two-fold dilutions 
from 0.09375-24 µM.  EC50 = 1.3 µM, as determined by interpolation by GraphPad software. 
 
Selectivity Indices.  The Selectivity Index (SI) is a comprehensive ranking of the 
safety and efficacy of a drug.  An SI value of 10 or greater was considered the 
cutoff for determining the best drugs.  Of the sixteen compounds for which an 
EC50 concentration was determined, ten had an SI greater than 10 and are 
candidates for future study (Table 2).  These ten highly effective compounds 
implicate a number of important pathways and enzymes necessary for VZV 
replication.  Amongst them are three growth factor receptor kinase inhibitors 
(Tyrphostin AG1478, Tyrphostin 9, and AG-879) and a number of their 
downstream effectors, including two protein kinase C inhibitors (PKC-412 and 
GF 109203X), two glycogen synthase kinase 3 beta (GSK-3β) inhibitors 
(Kenpaullone and Indirubin-3’-monooxime), a calmodulin-dependent protein 
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kinase (CaMKII) inhibitor (KN-62), a cyclin-dependent kinase (CDK) inhibitor 
(Roscovitine), and a protein kinase A inhibitor (H89  2HCl).  
 
Table 2.  Results of EC50 Assays and SI values.  Applied cytotoxicity represents the value used in 
calculating SI.  Regression curves could not be reliably fit for drugs marked * so their SI values may 
actually be larger than indicated.  Drugs marked ** were nontoxic at 100 µM so their SI values may actually 
be larger than shown.   
Drug Applied 
Cytotoxicity (µM) 
EC50 (µM) SI 
Tyrphostin AG1478
*
 
 
100
 
0.22 454.4 
PKC-412
*
 100 0.45 222.2 
Tyrphostin 9
**
 100 1.3 76.9 
Kenpaullone 100 2.9 34.5 
KN-62 25 0.86 29.1 
GF 109203X 50 1.9 26.3 
Indirubin-3’-monooxime 50 2.9 17.2 
Roscovitine 50 2.9 17.2 
H-89  2HCl 50 3.1 16.1 
AG-879 100 9.7 10.3 
N9-isopropyl-
olomoucine 
50 5.6 8.9 
Terreic Acid 25 3.1 8.1 
Triciribine
**
 100 13.0 7.7 
Tyrphostin 23
**
 100 13.2 7.6 
KN-93 25 4.3 5.8 
RG-1462 25 4.6 5.4 
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Discussion 
 
In this study we identified several important cellular kinases utilized by 
VZV during viral replication by inhibiting their activity with specific 
compounds.  Understanding the roles of the identified host proteins in the viral 
life cycle will expand our knowledge of VZV infection and has the potential to 
lead to novel approaches to antiviral therapy.   
The results of the Neutral Red Assay identified a number of inhibitors 
that were too toxic in non-infected cells to warrant further study.  The drugs used 
in this study were capable of causing deleterious consequences in host tissue ― 
they directly targeted mediators of cell survival, growth, differentiation, division, 
and gene expression pathways that are crucial elements of living systems.  Some 
of the drugs may prevent virus replication but at the cost of severely inhibiting 
host cellular processes or cell death.  This would, of course, limit the potential 
value of such a drug in treating a non-malignant illness like varicella or zoster.  
The concentrations used in these experiments (0-100 µM) were much higher than 
would be administered in a clinical setting, where it is difficult to achieve a 
concentration greater than 10 µM in vivo.  Compounds were required to be non-
toxic at 12.5 µM because this concentration was closest to the real-world value.  
We were confident that host cells would tolerate compounds that were non-toxic 
at 12.5 µM or higher.  This proved to be a reasonable cutoff, as it left us with 71 
of the original 80 compounds that were safe for use in cultured cells.  The 
eliminated compounds were simply too harsh and complications associated with 
their use could likely outweigh any potential antiviral activity.     
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Results of the cellular proliferation assay indicated that the majority of 
compounds tested did not severely inhibit cell division.  A non-toxic compound 
could still limit the rate of important metabolic processes crucial for normal cell 
activity without causing cell death.  Like cytotoxic compounds, inhibitors that 
cause such problems would not be useful in the clinical treatment of VZV.  The 
MTT Assay was performed to measure the effect of the inhibitors on cell growth 
and division.  The cutoff used for these experiments was 1.5 µM but, for a 
number of reasons, it was not as important or strictly applied as the toxicity 
cutoff.  For one, these compounds are designed to be anti-proliferative and, 
indeed, some of them are currently being studied as anti-cancer therapies 
(Giamas et al., 2010; Hidalgo & Rowinsky, 2000; Y. Zhang et al., 2008).  
Furthermore, most cells in vivo are not dividing, and, important for our purposes, 
VZV grows well in quiescent cells.  The cutoff for the MTT Assay may have 
been a bit too conservative, as it eliminated only one additional compound 
(Wortmannin) from the study.  The majority of the drugs used, however, 
including those that would prove most effective at blocking VZV replication, did 
not inhibit cell proliferation at the highest concentrations tested. 
Assessment of the antiviral capacity of the remaining compounds 
distinguished the ten most effective inhibitors of VZV replication.  Potency of 
compounds that were not eliminated by the Neutral Red or MTT Assays was first 
assessed by the Dose Response Assay, where a cutoff of twenty-percent viral 
yield at 12 µM was used to keep only the most efficacious inhibitors in the study 
for further analysis.  The 12 µM cutoff was selected for its proximity to the 
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attainable in vivo concentration of 10 µM and the Neutral Red cutoff used earlier.  
Application of these criteria narrowed the list of compounds to the sixteen most 
effective drugs and ten compounds remained after EC50 concentrations and SI 
values were calculated.  An SI value of 10 is the industry standard used in 
evaluating the potential of a compound for use in vivo and thus served as the 
cutoff in our study.  The limits used in selecting this final group of compounds 
proved to be appropriate: it is unlikely that any highly effective drugs were 
eliminated too early.  The rejected compounds simply lacked potency.  
The compounds highlighted by this study affect targets that are critical 
mediators of the viral lifecycle.  Identification of these targets as well as 
knowledge of their function has led to the development of a working model 
detailing their relationships and roles in VZV replication (Fig. 9).  Of the ten 
most promising drugs identified in this study, three (Tyrphostin AG1478, 
Tyrphostin 9, and AG-879) are selective inhibitors of growth factor receptor 
tyrosine kinases (GFRTKs).  This is a particularly exciting finding as the 
independent action of three inhibitors confirms the importance of these proteins 
as antiviral targets.  GFRTKs are subdivided into epidermal growth factor 
receptor kinases (EGFRK), platelet-derived growth factor receptor kinases 
(PDGFRK), and neuronal growth factor receptor kinases (NGFRK) that are 
expressed in the fibroblasts used in these experiments and many other cell types. 
GFRTKs are important membrane-bound signal transducing proteins that initiate 
cell-signaling cascades that activate, among others, the Ras, MAPK, PI3K, Akt, 
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and JAK pathways.  These pathways elicit a variety of responses that promote 
cell growth, proliferation, differentiation, survival, transcription factor 
production, and gene expression (Alberts et al., p. 555-567).  Given the multitude 
of activities initiated by these enzymes, GFRTKs have become a common target 
in the treatment of malignant and non-malignant disorders (Grimminger et al., 
2010).  Activation of both EGFRK and PDGFRK signaling are required for 
human cytomegalovirus (HCMV) infection, a member of the herpes virus family 
(Evers et al., 2004; Soroceanu et al., 2008).  Similarly, inhibition of GFRKs 
prevented viral pathogenesis during herpes simplex virus 1 (HSV-1) infection in 
mice (Sharma et al., 2011).  Moreover, AG-879 and Tyrphostin 9 exhibit 
antiviral activity against a wide variety of viruses including HSV-1 (Kumar et 
al., 2011).  It is no surprise then that the GFRTKs were implicated in this study 
as logical targets for the replication of VZV.  It is possible that VZV interacts 
with these receptor kinases before or upon entry into the host cell to activate 
mechanisms necessary for expression of viral proteins. 
 Two of the final ten drugs are Protein Kinase C (PKC) inhibitors (PKC-
412, GF 109203X).  Like the GFRTKs, the implication of two separate drugs as 
high quality treatments validates the essential role of PKC in VZV replication.  
The importance of PKC in modulating the VZV life cycle was confirmed by 
Bontems et al. (2002) when they demonstrated that PKC phosphorylates the 
VZV protein IE63, which is a key regulator of viral gene expression previously 
shown to be essential for virus replication by Sommer et al. (2001).  PKC is a 
central protein that is activated by a number of receptor signaling pathways, 
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including those initiated by the GFRTKs, which modulates a vast array of 
cellular processes.  PKC functions vary by cell type, but common responses 
include cell growth, transcription regulation, and alteration of membrane 
structure (Newton, 1995).  The activity of a multifunctional effector like PKC, in 
addition to its known interaction with viral proteins, makes it an important 
cellular target of VZV.   
 Two glycogen synthase kinase 3β (GSK-3β) inhibitors (Kenpaullone and 
Indirubin-3’-monooxime) were also potent antiviral compounds in the study.  
Like PKC, GSK-3β is another diverse signaling protein that regulates a variety of 
cellular functions.  Most notably, GSK-3β is involved in metabolism, gene 
expression, neuronal development, and regulation of cell death by facilitating 
apoptotic pathways (Grimes & Jope, 2001).  GSK-3β activity is regulated by 
epidermal growth factor (EGF) and the EGFRK pathway (Saito et al., 1994).  
The nature of this regulation appears to be inhibitory, however, so its role in 
preventing VZV replication is unclear.  Furthermore, GSK-3β is involved in both 
stimulatory and inhibitory crosstalk with a number of other signaling proteins 
like Protein Kinases A, B (Akt), and C (Grimes & Jope, 2001), making its role in 
VZV infection difficult to discern. 
 A Ca
2+
/Calmodulin-dependent protein kinase II (CaMKII) inhibitor, KN-
62, was also found to have antiviral activity by this analysis.  CaMKII requires 
activation by calcium
 
ions.  The relationship between VZV and intracellular 
calcium is poorly understood, but other viruses in the herpesviridae family are 
known to transiently increase the concentration of Ca
2+ 
ions to induce calcium-
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signaling pathways (Cheshenko et al., 2003).  CaMKII is another signaling hub 
that phosphorylates many downstream effector proteins and is thusly an 
important mediator in a number of pathways.  CaMKII is expressed in all 
eukaryotic cells (Alberts et al., 2010. p. 553) and, given its role in many signal 
transduction pathways, would be a logical target for VZV to hijack. 
 Roscovitine, a cyclin-dependent kinase (CDK) inhibitor, was also a drug 
of significant importance in our analysis.  Roscovitine has previously been 
shown to disrupt VZV replication (S. Taylor et al., 2004), further validating the 
findings of this study.  Moreover, Leisenfelder et al. (2008) showed that a CDK 
protein co-localized with and phosphorylated a VZV tegument protein in HFFs, 
providing evidence of a direct interaction between VZV and host CDKs.  CDKs 
regulate cell cycle progression and are targeted by herpes viruses to promote 
transcription and passage through the G1 phase of the cell cycle to the S phase 
where viral DNA is replicated (Hardwick, 2000).  This process is so important to 
viral replication, in fact, that many herpes viruses encode their own cyclin 
proteins to promote it (Mittnacht & Boshoff, 2000).  It is not surprising then that 
inhibition of these effectors resulted in prevention of VZV replication. 
 One final drug implicated by the panel analysis was H89  2HCl, an 
inhibitor of Protein Kinase A (PKA), which is homologous to PKC and is an 
important mediator in the activation of cellular transcription factors, which are 
required for VZV mRNA synthesis (Rahaus & Wolff, 2003).  A role of PKA in 
VZV infection was shown by Desloges et al. (2008) when they demonstrated that 
substrates of PKA are phosphorylated during VZV infection and that treatment 
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with an inhibitor of PKA dramatically reduced virus replication in fibroblasts.  
The effects of PKA activity vary depending on cell type, but it is certainly a 
crucial target for VZV.  
 Together, the results of this project have implicated specific host kinases 
as essential for VZV replication.  Although the identification of these proteins is 
an important first step in the development of antiviral medication, a number of 
additional assays would provide critical evidence of the roles and effectiveness of 
kinase inhibitors as therapy for varicella and zoster.  Five potential laboratory 
studies will be discussed here.   
 The first logical future study we would perform is the plaque assay, a 
more standard virology technique used to detect virus concentration in a sample.  
Plaque assays measure infectious particles such as virions, infected cells, or 
syncytia in a sample.  These particles form countable plaques (cleared areas) on a 
monolayer of confluent cells.  Each plaque represents an infectious particle 
present in the original sample.  Such an assay could be performed with the top 
ten drugs identified in this study to validate our results. 
 Second, we would analyze the activation or inhibition of the cellular 
proteins we identified as antiviral targets.  Cell kinases are typically regulated by 
phosphorylation on specific sites that can be detected by immunoblotting 
(Western blot) techniques (Rahaus et al., 2005).  To determine the effect of VZV 
on the identified proteins, the concentration of their phosphorylated forms would 
be compared in infected and uninfected cells as well as in the presence of their 
inhibitors. 
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 Third, time of addition studies would be performed to help us further 
understand the antiviral mechanisms of potent compounds.  Witvrouw et al. 
(1998) used this type of experiment to elucidate the mechanism of a drug that 
inhibits the replication of VZV and other viruses.  In this assay, drugs are added 
to virus-infected cells at various times before and after infection.  Virus 
replication is later quantified and the results may point to the phase of the virus 
lifecycle that is blocked by the compound.  Some of the drugs identified in our 
study may have much lower EC50 values before, during, or after infection 
depending on the phase of infection they inhibit.  Such a change in the EC50 
concentration could make a compound even more effective than suggested by 
this study if administered under the right conditions.  The results of treatment 
with GFRTK inhibitors would be of considerable interest in such an experiment 
because it is possible that prophylactic administration of these compounds could 
prevent virally mediated host-signaling and virus replication altogether.  This 
would be important in the treatment of immunocompromised individuals who are 
at high risk for zoster.  Results of time of addition studies would have a direct 
implication on how therapeutic compounds targeting these proteins would be 
used in a clinical setting. 
 Fourth, we would perform combination assays that could yield valuable 
information regarding synergistic or antagonistic interactions between the kinase 
inhibitors we identified and current antiviral medications.  Such approaches have 
been used to demonstrate the additive antiviral effects of antiherpes drugs and 
interferon in treating VZV and HSV-1 (Baba et al., 1984; J. Taylor et al., 1998).  
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Combination therapy is common for many malignant and non-malignant diseases 
and is used most notably in the treatment of HIV and hepatitis C.  In this case, 
the use of multiple kinase inhibitors may synergistically shut down a number of 
crucial pathways and have greater antiviral activity than the independent effect of 
each drug alone.  Alternatively, because some of the targets identified in this 
study regulate the activity of others, it is possible that co-inhibition may cancel 
the effects of the individual inhibitors.  These drugs can also be combined with 
current medications to block viral replication by two separate mechanisms, which 
could further suppress the development of drug resistance.   
 Finally, compounds that showed promise in cultured cells could be tested 
in vivo in a severe combined immunodeficient (SCID) mouse model.  The SCID 
model is commonly used in the assessment of VZV pathogenesis (Arvin, 2006; 
Ku et al., 2005; Zerboni et al., 2010).  In these assays, SCID mice are implanted 
with human skin and then VZV is inoculated directly into the tissue.  The mice 
are treated with antiviral drugs and virus yield is measured by in vivo 
bioluminescence (Rowe, et al, 2010).  Because the immune systems of SCID 
mice have been completely removed, any effect on viral replication is the result 
of treatment.  This process is important in identifying how these drugs fit into a 
clinical setting and determining the proper route of administration (i.e., topically 
or systemically).  Information from these studies would shed light on the 
processing of drugs in an in vivo tissue environment.  This is a crucial step in 
assessing the potency and safety of drugs in a living system and serves as the 
bridge from bench to bedside. 
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 Together, the results of this study have highlighted several important 
cellular targets of VZV and expanded our understanding of host-virus 
interactions that have the potential to lead to new treatments of VZV infection.  
Although the findings of this project provide further evidence of the merits of the 
host-centered paradigm, the medical community as a whole has thus far been 
resistant to accept this chemotherapeutic approach to treating varicella and 
zoster.  We hope that the results of this project will strengthen the perception of 
these methods in combating these diseases and lead to continued efforts in the 
development of host-targeted antivirals.   
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